Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Reggio Emilia – page 25

731 clinical trials in Reggio Emilia, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Reggio Emilia at a glance
731
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

731 trials in Reggio Emilia

Open in trial search

Systemic scleroderma+1

Not yet recruiting

Study of Amlitelimab and BI 1015550 for Patients with Interstitial Lung Disease Due to Scleroderma

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Scleroderma Research Foundation

Endometrial cancer

Not yet recruiting

Maintenance Treatment Study of gsk5733584 with dostarlimab or pembrolizumab in patients with mismatch repair proficient advanced or recurrent endometrial cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Ischaemic stroke

Not yet recruiting

Study on Fibrinogen Replacement to Prevent Brain Bleeding in Stroke Patients After Thrombolysis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Human Fibrinogen
  • Sponsor:Azienda Unita Sanitaria Locale Di Bologna

Malignant peritoneal neoplasm+2

Not yet recruiting

A Phase 3 Study of Raludotatug Deruxtecan With or Without Bevacizumab as Maintenance Therapy in Patients With Platinum‑Sensitive Recurrent Ovarian Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Daiichi Sankyo Inc.

Phase 2 Study of Inhaled AGMB-447 and Salbutamol Sulfate in Adults with Idiopathic Pulmonary Fibrosis to Evaluate Lung Function, Safety and Tolerability

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol Sulfate
  • Sponsor:Agomab Spain S.L.

Transitional cell carcinoma+1

Not yet recruiting

Phase 3 Study of trastuzumab brengitecan versus platinum‑based chemotherapy in adults with HER2‑positive metastatic urothelial cancer after anti‑PD‑(L)1 therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Systimmune Inc.

Multiple sclerosis

Not yet recruiting

Long‑Term Safety and Tolerability of Frexalimab Drug Combination in Adults with Multiple Sclerosis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Colestyramine
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Breast cancer+2

Not yet recruiting

Gedatolisib with drug combination versus standard therapy as first‑line treatment for patients with advanced HR‑positive HER2‑negative breast cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Celcuity Inc.

Adenocarcinoma gastric+1

Not yet recruiting

A Phase 3 Study of ASP2138 Plus Drug Combination in Adults with HER2‑Negative, CLDN18.2‑Positive Advanced Gastric Cancer (First‑Line Treatment)

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Peripheral venous disease

Not yet recruiting

Efficacy and Safety of Heparan Sulphate 120 mg Prolonged‑Release Tablets in Patients with Primary Chronic Venous Disease of the Lower Limbs

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Farmaceutici Damor S.p.A.

Osimertinib and drug combination in metastatic non‑small cell lung cancer with targetable genomic driver alterations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Universita' Degli Studi Di Torino

VEXAS syndrome

Not yet recruiting

A Randomized, Double‑Blind, Placebo‑Controlled Study of Momelotinib Dihydrochloride Monohydrate in Patients with VEXAS Syndrome

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Momelotinib Dihydrochloride Monohydrate
  • Sponsor:Glaxosmithkline Research & Development Limited

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Reggio Emilia

What the registry says about research in the country

01 Oncology - Solid Tumors

Innovative clinical trials focusing on metastatic colorectal cancer, non-small cell lung cancer, and gastric cancer. Research evaluates novel therapeutic approaches including targeted therapies and immunotherapy combinations.

  • Colorectal Cancer Treatments
  • Lung Cancer Therapies
  • Gastrointestinal Oncology

Studies include assessment of treatment efficacy and novel drug combinations for advanced stage cancers.

02 Hematologic Malignancies

Groundbreaking research in B-cell lymphomas and chronic myeloid leukemia. Studies evaluate innovative treatment approaches including targeted therapies and combination protocols.

  • Lymphoma Treatments
  • Leukemia Therapies
  • Novel Drug Combinations

Focus on improving patient outcomes through personalized treatment approaches.

03 Autoimmune Conditions

Clinical trials investigating treatments for Sjögren's Syndrome and other inflammatory conditions. Research aims to evaluate long-term safety and efficacy of novel therapeutic agents.

  • Inflammatory Disorders
  • Autoimmune Diseases
  • Novel Therapeutics

Studies focus on developing safer and more effective treatment options for patients.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.